• Je něco špatně v tomto záznamu ?

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies

RH. Kobayashi, S. Gupta, I. Melamed, JF. Mandujano, AL. Kobayashi, B. Ritchie, B. Geng, TP. Atkinson, S. Rehman, E. Turpel-Kantor, J. Litzman,

. 2019 ; 10 (-) : 40. [pub] 20190204

Jazyk angličtina Země Švýcarsko

Typ dokumentu kazuistiky, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19044985

Introduction: Subcutaneously administered immunoglobulin (SCIG) is increasingly used to treat patients with primary immunodeficiencies (PIDs). Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®. Objectives: To investigate the efficacy, safety and tolerability of octanorm in a prospective, open-label, single-arm phase 3 study involving adult and pediatric patients with PIDs (NCT01888484; clinicaltrials.gov/ct2/show/NCT01888484). Methods: Patients who were previously treated with IVIG received a total of 64 weekly SCIG infusions, including 12 weekly infusions during the wash-in/wash-out period, followed by 52 weekly infusions during the evaluation period. Results: A total of 61 patients aged 2-73 years received 3,497 infusions of octanorm. The mean dose per patient was 0.175 g/kg/infusion. The mean calculated dose conversion factor from the patients' previous IVIG dose for octanorm was 1.37. No serious bacterial infections developed during the study. The rate of other infections per person-year during the primary observation period was 3.43 (upper 95% CI 4.57). All but one non-bacterial infection were mild or moderate in intensity. IgG trough levels were constant during the course of the study. Eleven patients (18.0%) experienced 14 mild or moderate systemic adverse events (AEs) related to octanorm. The rate of related AEs per infusion was 0.004. In 76.7% of infusions, no infusion site reactions were observed and only two (0.3%) reactions were deemed severe. The incidence of site reactions decreased with successive infusions. Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044985
003      
CZ-PrNML
005      
20200113081541.0
007      
ta
008      
200109s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2019.00040 $2 doi
035    __
$a (PubMed)30778345
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kobayashi, Roger H $u UCLA School of Medicine, Los Angeles, CA, United States.
245    10
$a Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies / $c RH. Kobayashi, S. Gupta, I. Melamed, JF. Mandujano, AL. Kobayashi, B. Ritchie, B. Geng, TP. Atkinson, S. Rehman, E. Turpel-Kantor, J. Litzman,
520    9_
$a Introduction: Subcutaneously administered immunoglobulin (SCIG) is increasingly used to treat patients with primary immunodeficiencies (PIDs). Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®. Objectives: To investigate the efficacy, safety and tolerability of octanorm in a prospective, open-label, single-arm phase 3 study involving adult and pediatric patients with PIDs (NCT01888484; clinicaltrials.gov/ct2/show/NCT01888484). Methods: Patients who were previously treated with IVIG received a total of 64 weekly SCIG infusions, including 12 weekly infusions during the wash-in/wash-out period, followed by 52 weekly infusions during the evaluation period. Results: A total of 61 patients aged 2-73 years received 3,497 infusions of octanorm. The mean dose per patient was 0.175 g/kg/infusion. The mean calculated dose conversion factor from the patients' previous IVIG dose for octanorm was 1.37. No serious bacterial infections developed during the study. The rate of other infections per person-year during the primary observation period was 3.43 (upper 95% CI 4.57). All but one non-bacterial infection were mild or moderate in intensity. IgG trough levels were constant during the course of the study. Eleven patients (18.0%) experienced 14 mild or moderate systemic adverse events (AEs) related to octanorm. The rate of related AEs per infusion was 0.004. In 76.7% of infusions, no infusion site reactions were observed and only two (0.3%) reactions were deemed severe. The incidence of site reactions decreased with successive infusions. Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a pasivní imunizace $x metody $7 D007116
650    _2
$a imunoglobulin G $x aplikace a dávkování $x krev $7 D007074
650    _2
$a intravenózní imunoglobuliny $x aplikace a dávkování $x farmakokinetika $x terapeutické užití $7 D016756
650    _2
$a syndromy imunologické nedostatečnosti $x farmakoterapie $7 D007153
650    _2
$a subkutánní infuze $7 D055104
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mladý dospělý $7 D055815
655    _2
$a kazuistiky $7 D002363
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Gupta, Sudhir $u Division of Basic and Clinical Immunology, University of California, Irvine, Irvine, CA, United States.
700    1_
$a Melamed, Isaac $u IMMUNOe Research Center, Centennial, CO, United States.
700    1_
$a Mandujano, J Fernando $u Pediatric Pulmonary Associates of North Texas, Frisco, TX, United States.
700    1_
$a Kobayashi, Ai Lan $u Midlands Pediatrics, Papillion, NE, United States.
700    1_
$a Ritchie, Bruce $u Division of Hematology, Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada.
700    1_
$a Geng, Bob $u Divisions of Adult and Pediatric Allergy and Immunology, University of California, San Diego, La Jolla, CA, United States.
700    1_
$a Atkinson, Thomas Prescott $u Department of Pediatric Allergy, Asthma and Immunology, University of Alabama, Birmingham, AL, United States.
700    1_
$a Rehman, Syed $u Allergy and Asthma Center Inc., Toledo, OH, United States.
700    1_
$a Turpel-Kantor, Eva $u Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria.
700    1_
$a Litzman, Jiří $u Department of Clinical Immunology and Allergology, St Anne's University Hospital in Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 10, č. - (2019), s. 40
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30778345 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113081913 $b ABA008
999    __
$a ok $b bmc $g 1483254 $s 1083658
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 10 $c - $d 40 $e 20190204 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace